SI
DYN icon

Sofinnova Investments’s Dyne Therapeutics DYN Stock Holding History

Sofinnova Investments’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.8M Buy
1,658,384
+24,487
+1% +$455K 1.9% 18
2026
Q1 		$29.6M Sell
1,633,897
-620,264
-28% -$10.7M 1.13% 32
2025
Q4 		$44.1M Buy
2,254,161
+1,268,333
+129% +$24M 1.9% 15
2025
Q3 		$12.5M Buy
985,828
+370,963
+60% +$4.23M 0.68% 40
2025
Q2 		$5.85M Sell
614,865
-102,031
-14% -$1.12M 0.36% 48
2025
Q1 		$7.5M Sell
716,896
-354,602
-33% -$5.07M 0.49% 45
2024
Q4 		$25.2M Buy
1,071,498
+299,428
+39% +$8.86M 1.84% 19
2024
Q3 		$27.7M Sell
772,070
-853,633
-53% -$34M 2.2% 14
2024
Q2 		$57.4M Sell
1,625,703
-310,947
-16% -$9.04M 2.98% 9
2024
Q1 		$55M Buy
1,936,650
+923,145
+91% +$20.9M 3.06% 11
2023
Q4 		$13.5M Buy
1,013,505
+328,372
+48% +$3.21M 0.75% 31
2023
Q3 		$6.14M Buy
685,133
+244,085
+55% +$2.63M 0.39% 44
2023
Q2 		$4.96M Buy
+441,048
New +$5.2M 0.33% 37

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Sofinnova Investments's DYN Position: Q2 2026 in Review

Sofinnova Investments increased its Dyne Therapeutics (DYN) stake by 1.5% in Q2 2026, buying an estimated $455K and bringing the position to 1,658,384 shares worth $36.8M. The position accounts for 1.9% of the portfolio, ranked #18.

Sofinnova Investments first reported a position in DYN in Q2 2023 and has held it in 13 quarters since. The position peaked at $57.4M in Q2 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Sofinnova Investments held 1,658,384 shares of Dyne Therapeutics worth $36.8M as of Q2 2026.
  • Sofinnova Investments bought 24,487 Dyne Therapeutics shares in Q2 2026, an estimated $455K.
  • Dyne Therapeutics made up 1.9% of Sofinnova Investments's portfolio in Q2 2026, its #18 holding.
  • Sofinnova Investments first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Sofinnova Investments's Dyne Therapeutics position peaked at $57.4M in Q2 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.